SCHEMBL16291539

SCHEMBL16291539

CCN(CCN(C)C)C(=O)CNCc1cc(C(=O)Oc2c(OC(C)C)cccc2OC(C)C)ccn1

nearest known ligand 0.77

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM5B Q9UGL1 14/20 0.77
▸ KDM5C P41229 8/20 0.77
▸ KDM5A P29375 7/20 0.77
▸ KDM4C Q9H3R0 2/20 0.68
▸ KDM4A O75164 2/20 0.63
▸ KDM6B O15054 1/20 0.63
▸ KDM2B Q8NHM5 1/20 0.63
▸ KDM5D Q9BY66 1/20 0.62
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ ACKR3 P25106 2/20 0.34
▸ HCRTR1 O43613 2/20 0.34
▸ HCRTR2 O43614 2/20 0.34
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21716662 0.92 KDM5B (0.84) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL21716654 0.91 KDM5B (0.64) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL26862784 0.90 KDM5B (0.71) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL21716663 0.87 KDM5B (1.00) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL21716656 0.87 KDM5B (0.59) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL21716677 0.87 KDM5B (0.74) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL21716669 0.86 KDM5B (0.67) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL26862785 0.84 KDM5B (0.72) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL16912751 0.84 KDM5B (0.55) KDM5BKDM5CKDM5AKDM4CKDM4A
SCHEMBL21716659 0.83 KDM5B (0.64) KDM5BKDM5CKDM5AKDM4CKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382865-A1 HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-30 — — US disclosed
US-20230382865-A1 HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-30 — — US disclosed
WO-2020033377-A1 HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-13 — — WO disclosed
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
US-9611219-B2 — — 2017-04-04 — — US disclosed
US-9611219-B2 — — 2017-04-04 — — US disclosed
EP-2903968-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2016-12-07 — — EP disclosed
EP-2903968-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2016-12-07 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382865-A1 HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF KDM5A, KDM5B, KDM5C KDM5B 2/4885KDM5C 3/4885KDM5A 1/4885
US-10189787-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM5B 34/4885KDM5C 31/4885KDM5A 25/4885
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885
US-10221139-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback